ArticleNature communications2026

Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer.

Yaoyu Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.